Ascendis Pharma A/S (ASND)
NasdaqGS
Price as at 1 Oct 2026, 19:46 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Ascendis Pharma A/S trades at $226.93. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Politician trades in ASND
Trades in ASND disclosed by members of Congress and executive-branch officials, latest first:
- Gary Palmer · HouseSell · $1,001 - $15,000 · traded 5 Oct 2018 · disclosed 7 Nov 2018
- Gary Palmer · HouseBuy · $1,001 - $15,000 · traded 6 Aug 2018 · disclosed 29 Sept 2018
- Gary Palmer · HouseBuy · $1,001 - $15,000 · traded 12 Jul 2018 · disclosed 29 Sept 2018
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Where does SteadyShares get its ASND data?
Fundamentals for ASND come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 19:46 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ASND, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.